|
|
![]() |
![]() |
![]() |
|
|||||||
![]() |
|||
Innovation at LacProOur initial research is focused broadly on gastrointestinal ailments, with a specific emphasis on therapies for Clostridium difficile Infection (CDI). Our aim is to produce groundbreaking medical foods and biotherapeutics to improve patients’ lives and reduce the total cost of health care treatments in hospitals and long-term care facilities. Our proprietary probiotic strain, Lactobacillus delbrueckii spp. bulgaricus B-30892 (LDB B-30892), has demonstrated effectiveness in outpatient, hospital and long-term care facility settings for patients and residents with CDI, Inflammatory Bowel Disease. |
|||
![]() |